Hôpital Claude Huriez, Services Maladies de l'Appareil Digestif and INSERM Unité 995, CHRU Lille, Lille, France.
Hôpital Claude Huriez, Services Maladies de l'Appareil Digestif and INSERM Unité 995, CHRU Lille, Lille, France.
J Hepatol. 2017 Oct;67(4):708-715. doi: 10.1016/j.jhep.2017.06.009. Epub 2017 Jun 21.
BACKGROUND & AIMS: Liver transplantation (LT) for the most severely ill patients with cirrhosis, with multiple organ dysfunction (accurately assessed by the acute-on-chronic liver failure [ACLF] classification) remains controversial. We aimed to report the results of LT in patients with ACLF grade 3 and to compare these patients to non-transplanted patients with cirrhosis and multiple organ dysfunction as well as to patients transplanted with lower ACLF grade.
All patients with ACLF-3 transplanted in three liver intensive care units (ICUs) were retrospectively included. Each patient with ACLF-3 was matched to a) non-transplanted patients hospitalized in the ICU with multiple organ dysfunction, or b) control patients transplanted with each of the lower ACLF grades (three groups).
Seventy-three patients were included. These severely ill patients were transplanted following management to stabilize their condition with a median of nine days after admission (progression of mean organ failure from 4.03 to 3.67, p=0.009). One-year survival of transplanted patients with ACLF-3 was higher than that of non-transplanted controls: 83.9 vs. 7.9%, p<0.0001. This high survival rate was not different from that of matched control patients with no ACLF (90%), ACLF-1 (82.3%) or ACLF-2 (86.2%). However, a higher rate of complications was observed (100 vs. 51.2 vs. 76.5 vs. 74.3%, respectively), with a longer hospital stay. The notion of a "transplantation window" is discussed.
LT strongly influences the survival of patients with cirrhosis and ACLF-3 with a 1-year survival similar to that of patients with a lower grade of ACLF. A rapid decision-making process is needed because of the short "transplantation window" suggesting that patients with ACLF-3 should be rapidly referred to a specific liver ICU. Lay summary: Liver transplantation improves survival of patients with very severe cirrhosis. These patients must be carefully monitored and managed in a specialized unit. The decision to transplant a patient must be quick to avoid a high risk of mortality.
对于患有肝硬化和多器官功能障碍(通过慢性肝衰竭急性加重(ACLF)分类准确评估)的最病重患者,肝移植(LT)仍然存在争议。我们旨在报告 LT 治疗 ACLF 3 级患者的结果,并将这些患者与未接受移植的肝硬化和多器官功能障碍患者以及接受较低 ACLF 级别的患者进行比较。
回顾性纳入了在三个肝重症监护病房(ICU)接受 LT 的所有 ACLF-3 患者。每位 ACLF-3 患者与 a)入住 ICU 伴有多器官功能障碍但未接受移植的患者,或 b)接受每个较低 ACLF 级别的对照患者(三组)进行匹配。
共纳入 73 例患者。这些病重患者在病情稳定后接受移植,中位时间为入院后 9 天(器官衰竭平均值从 4.03 进展到 3.67,p=0.009)。移植后 ACLF-3 患者的 1 年生存率高于未接受移植的对照组:83.9%比 7.9%,p<0.0001。这一高生存率与无 ACLF 的匹配对照患者(90%)、ACLF-1(82.3%)或 ACLF-2(86.2%)患者无差异。然而,观察到更高的并发症发生率(分别为 100%比 51.2%比 76.5%比 74.3%),且住院时间更长。讨论了“移植窗”的概念。
LT 强烈影响 ACLF-3 肝硬化患者的生存,1 年生存率与较低 ACLF 级别的患者相似。由于“移植窗”较短,需要快速决策过程,这表明 ACLF-3 患者应迅速转至专门的肝 ICU。
肝移植可提高严重肝硬化患者的生存率。这些患者必须在专门的单位接受仔细监测和管理。决定移植患者必须迅速做出,以避免高死亡率风险。